| Last Version Text |
<?xml version="1.0" ?>
<ns0:MeasureDoc xmlns:html="http://www.w3.org/1999/xhtml" xmlns:ns0="http://lc.ca.gov/legalservices/schemas/caml.1#" xmlns:ns3="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" version="1.0" xsi:schemaLocation="http://lc.ca.gov/legalservices/schemas/caml.1# xca.1.xsd">
<ns0:Description>
<ns0:Id>20250AB__005096CHP</ns0:Id>
<ns0:VersionNum>96</ns0:VersionNum>
<ns0:History>
<ns0:Action>
<ns0:ActionText>INTRODUCED</ns0:ActionText>
<ns0:ActionDate>2024-12-02</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>AMENDED_ASSEMBLY</ns0:ActionText>
<ns0:ActionDate>2025-04-02</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>PASSED_ASSEMBLY</ns0:ActionText>
<ns0:ActionDate>2025-04-28</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>PASSED_SENATE</ns0:ActionText>
<ns0:ActionDate>2025-09-08</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>ENROLLED</ns0:ActionText>
<ns0:ActionDate>2025-09-10</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>CHAPTERED</ns0:ActionText>
<ns0:ActionDate>2025-09-26</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>APPROVED</ns0:ActionText>
<ns0:ActionDate>2025-09-26</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>FILED</ns0:ActionText>
<ns0:ActionDate>2025-09-26</ns0:ActionDate>
</ns0:Action>
</ns0:History>
<ns0:LegislativeInfo>
<ns0:SessionYear>2025</ns0:SessionYear>
<ns0:SessionNum>0</ns0:SessionNum>
<ns0:MeasureType>AB</ns0:MeasureType>
<ns0:MeasureNum>50</ns0:MeasureNum>
<ns0:MeasureState>CHP</ns0:MeasureState>
<ns0:ChapterYear>2025</ns0:ChapterYear>
<ns0:ChapterType>CHP</ns0:ChapterType>
<ns0:ChapterSessionNum>0</ns0:ChapterSessionNum>
<ns0:ChapterNum>135</ns0:ChapterNum>
</ns0:LegislativeInfo>
<ns0:AuthorText authorType="LEAD_AUTHOR">Introduced by Assembly Member Bonta</ns0:AuthorText>
<ns0:Authors>
<ns0:Legislator>
<ns0:Contribution>LEAD_AUTHOR</ns0:Contribution>
<ns0:House>ASSEMBLY</ns0:House>
<ns0:Name>Bonta</ns0:Name>
</ns0:Legislator>
</ns0:Authors>
<ns0:Title> An act to amend Sections 733, 4052, 4052.3, and 4064.5 of the Business and Professions Code, relating to healing arts, and declaring the urgency thereof, to take effect immediately. </ns0:Title>
<ns0:RelatingClause>healing arts, and declaring the urgency thereof, to take effect immediately</ns0:RelatingClause>
<ns0:GeneralSubject>
<ns0:Subject>Pharmacists: furnishing contraceptives.</ns0:Subject>
</ns0:GeneralSubject>
<ns0:DigestText>
<html:p>Existing law, the Pharmacy Law, establishes in the Department of Consumer Affairs the California State Board of Pharmacy to license and regulate the practice of pharmacy. Exiting law requires a pharmacist, when furnishing self-administered hormonal contraceptives, to follow specified standardized procedures or protocols developed and approved by both the board and the Medical Board of California in consultation with the American Congress of Obstetricians and Gynecologists, the California Pharmacists Association, and other appropriate entities. Existing law requires those standardized procedures or protocols to require that the patient use a self-screening tool that will identify related patient risk factors and that require the pharmacist to refer the patient for appropriate followup care, as specified. Existing law requires the pharmacist to provide the recipient of the drug with a
standardized factsheet that includes the indications and contraindications for use of the drug, the appropriate method for using the drug, the need for medical followup, and other appropriate information. Existing law authorizes a pharmacist furnishing an FDA-approved, self-administered hormonal contraceptive pursuant to the above-described protocols to furnish, at the patient’s request, up to a 12-month supply at one time.</html:p>
<html:p>This bill would limit the application of those requirements to self-administered hormonal contraceptives that are prescription-only, and would authorize a pharmacist to furnish over-the-counter contraceptives without following those standardized procedures or protocols.
The bill would additionally authorize a pharmacist to furnish up to a 12-month supply at one time of over-the-counter contraceptives at the patient’s request. The bill would make related conforming changes.</html:p>
<html:p>This bill would declare that it is to take effect immediately as an urgency statute.</html:p>
</ns0:DigestText>
<ns0:DigestKey>
<ns0:VoteRequired>TWO_THIRDS</ns0:VoteRequired>
<ns0:Appropriation>NO</ns0:Appropriation>
<ns0:FiscalCommittee>YES</ns0:FiscalCommittee>
<ns0:LocalProgram>NO</ns0:LocalProgram>
</ns0:DigestKey>
<ns0:MeasureIndicators>
<ns0:ImmediateEffect>YES</ns0:ImmediateEffect>
<ns0:ImmediateEffectFlags>
<ns0:Urgency>YES</ns0:Urgency>
<ns0:TaxLevy>NO</ns0:TaxLevy>
<ns0:Election>NO</ns0:Election>
<ns0:UsualCurrentExpenses>NO</ns0:UsualCurrentExpenses>
<ns0:BudgetBill>NO</ns0:BudgetBill>
<ns0:Prop25TrailerBill>NO</ns0:Prop25TrailerBill>
</ns0:ImmediateEffectFlags>
</ns0:MeasureIndicators>
</ns0:Description>
<ns0:Bill id="bill">
<ns0:Preamble>The people of the State of California do enact as follows:</ns0:Preamble>
<ns0:BillSection id="id_DC6FB1B7-F5A4-45B5-854E-6377EBFBA9E2">
<ns0:Num>SECTION 1.</ns0:Num>
<ns0:ActionLine action="IS_AMENDED" ns3:href="urn:caml:codes:BPC:caml#xpointer(%2Fcaml%3ALawDoc%2Fcaml%3ACode%2Fcaml%3ALawHeading%5B%40type%3D'DIVISION'%20and%20caml%3ANum%3D'2.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'CHAPTER'%20and%20caml%3ANum%3D'1.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'ARTICLE'%20and%20caml%3ANum%3D'10.5.'%5D%2Fcaml%3ALawSection%5Bcaml%3ANum%3D'733.'%5D)" ns3:label="fractionType: LAW_SECTION" ns3:type="locator">
Section 733 of the
<ns0:DocName>Business and Professions Code</ns0:DocName>
is amended to read:
</ns0:ActionLine>
<ns0:Fragment>
<ns0:LawSection id="id_7A81A4B6-6A18-42ED-AAE8-C692FE1D1690">
<ns0:Num>733.</ns0:Num>
<ns0:LawSectionVersion id="id_29837878-AF95-41E6-BEC6-8C3B9830F46C">
<ns0:Content>
<html:p>
(a)
<html:span class="EnSpace"/>
A licentiate shall not obstruct a patient in obtaining a prescription drug or device that has been legally prescribed or ordered for that patient. A violation of this section constitutes unprofessional conduct by the licentiate and shall subject the licentiate to disciplinary or administrative action by their licensing agency.
</html:p>
<html:p>
(b)
<html:span class="EnSpace"/>
Notwithstanding any other law, a licentiate shall dispense drugs and devices, as described in subdivision (a) of Section 4024, pursuant to a lawful order or prescription unless one of the following circumstances exists:
</html:p>
<html:p>
(1)
<html:span class="EnSpace"/>
Based solely on the licentiate’s professional training and judgment,
dispensing pursuant to the order or the prescription is contrary to law, or the licentiate determines that the prescribed drug or device would cause a harmful drug interaction or would otherwise adversely affect the patient’s medical condition.
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
The prescription drug or device is not in stock. If an order, other than an order described in Section 4019, or prescription cannot be dispensed because the drug or device is not in stock, the licentiate shall take one of the following actions:
</html:p>
<html:p>
(A)
<html:span class="EnSpace"/>
Immediately notify the patient and arrange for the drug or device to be delivered to the site or directly to the patient in a timely manner.
</html:p>
<html:p>
(B)
<html:span class="EnSpace"/>
Promptly transfer the prescription to another pharmacy known to stock the prescription
drug or device that is near enough to the site from which the prescription or order is transferred, to ensure the patient has timely access to the drug or device.
</html:p>
<html:p>
(C)
<html:span class="EnSpace"/>
Return the prescription to the patient and refer the patient. The licentiate shall make a reasonable effort to refer the patient to a pharmacy that stocks the prescription drug or device that is near enough to the referring site to ensure that the patient has timely access to the drug or device.
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
The licentiate refuses on ethical, moral, or religious grounds to dispense a drug or device pursuant to an order or prescription. A licentiate may decline to dispense a prescription drug or device on this basis only if the licentiate has previously notified
their employer, in writing, of the drug or class of drugs to which the licentiate objects, and the licentiate’s employer can, without creating undue hardship, provide a reasonable accommodation of the licentiate’s objection. The licentiate’s employer shall establish protocols that ensure that the patient has timely access to the prescribed drug or device despite the licentiate’s refusal to dispense the prescription or order. For purposes of this section, “reasonable accommodation” and “undue hardship” shall have the same meaning as applied to those terms pursuant to subdivision (l) of Section 12940 of the Government Code.
</html:p>
<html:p>
(c)
<html:span class="EnSpace"/>
For the purposes of this section, “prescription drug or device” has the same meaning as the definition in Section 4022.
</html:p>
<html:p>
(d)
<html:span class="EnSpace"/>
This section
applies to emergency contraception drug therapy, over-the-counter contraceptives, and self-administered prescription-only hormonal contraceptives described in Section 4052.3.
</html:p>
<html:p>
(e)
<html:span class="EnSpace"/>
This section imposes no duty on a licentiate to dispense a drug or device pursuant to a prescription or order without payment for the drug or device, including payment directly by the patient or through a third-party payer accepted by the licentiate or payment of any required copayment by the patient.
</html:p>
<html:p>
(f)
<html:span class="EnSpace"/>
The notice to consumers required by Section 4122 shall include a statement that describes patients’ rights relative to the requirements
of this section.
</html:p>
</ns0:Content>
</ns0:LawSectionVersion>
</ns0:LawSection>
</ns0:Fragment>
</ns0:BillSection>
<ns0:BillSection id="id_E2FB2089-326C-4C2C-B099-26BB2F5C10BD">
<ns0:Num>SEC. 2.</ns0:Num>
<ns0:ActionLine action="IS_AMENDED" ns3:href="urn:caml:codes:BPC:caml#xpointer(%2Fcaml%3ALawDoc%2Fcaml%3ACode%2Fcaml%3ALawHeading%5B%40type%3D'DIVISION'%20and%20caml%3ANum%3D'2.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'CHAPTER'%20and%20caml%3ANum%3D'9.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'ARTICLE'%20and%20caml%3ANum%3D'3.'%5D%2Fcaml%3ALawSection%5Bcaml%3ANum%3D'4052.'%5D)" ns3:label="fractionType: LAW_SECTION" ns3:type="locator">
Section 4052 of the
<ns0:DocName>Business and Professions Code</ns0:DocName>
is amended to read:
</ns0:ActionLine>
<ns0:Fragment>
<ns0:LawSection id="id_366AC690-11CE-4471-A974-B559F1872F4F">
<ns0:Num>4052.</ns0:Num>
<ns0:LawSectionVersion id="id_DEC27F28-AEB2-443F-8226-1AE3E0542405">
<ns0:Content>
<html:p>
(a)
<html:span class="EnSpace"/>
Notwithstanding any other law, a pharmacist may do all of the following:
</html:p>
<html:p>
(1)
<html:span class="EnSpace"/>
Furnish a reasonable quantity of compounded drug product to a prescriber for office use by the prescriber.
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
Transmit a valid prescription to another pharmacist.
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
Administer drugs and biological products that have been ordered by a prescriber.
</html:p>
<html:p>
(4)
<html:span class="EnSpace"/>
Perform procedures or functions in a licensed health care facility as authorized by Section 4052.1.
</html:p>
<html:p>
(5)
<html:span class="EnSpace"/>
Perform procedures or functions as part of the care provided by a health care facility, a licensed home health agency, a licensed clinic in which there is physician oversight, a provider who contracts with a licensed health care service plan with regard to the care or services provided to the enrollees of that health care service plan, or a physician, as authorized by Section 4052.2.
</html:p>
<html:p>
(6)
<html:span class="EnSpace"/>
Perform procedures or functions as authorized by Section 4052.6.
</html:p>
<html:p>
(7)
<html:span class="EnSpace"/>
Manufacture, measure, fit to the patient, or sell and repair dangerous devices, or furnish instructions to the patient or the patient’s representative concerning the use of those devices.
</html:p>
<html:p>
(8)
<html:span class="EnSpace"/>
Provide consultation, training, and education to patients about drug
therapy, disease management, and disease prevention.
</html:p>
<html:p>
(9)
<html:span class="EnSpace"/>
Provide professional information, including clinical or
pharmacological information, advice, or consultation to other health care professionals, and participate in multidisciplinary review of patient progress, including appropriate access to medical records.
</html:p>
<html:p>
(10)
<html:span class="EnSpace"/>
Furnish the medications described in subparagraph (A) in accordance with subparagraph (B):
</html:p>
<html:p>
(A)
<html:span class="EnSpace"/>
(i)
<html:span class="EnSpace"/>
Emergency contraception drug therapy, over-the-counter contraceptives, and self-administered prescription-only hormonal contraceptives, as authorized by Section 4052.3.
</html:p>
<html:p>
(ii)
<html:span class="EnSpace"/>
Nicotine replacement products, as authorized by Section 4052.9.
</html:p>
<html:p>
(iii)
<html:span class="EnSpace"/>
Prescription medications not requiring a diagnosis that are recommended
by the federal Centers for Disease Control and Prevention for individuals traveling outside of the United States.
</html:p>
<html:p>
(iv)
<html:span class="EnSpace"/>
HIV preexposure prophylaxis, as authorized by Section 4052.02.
</html:p>
<html:p>
(v)
<html:span class="EnSpace"/>
HIV postexposure prophylaxis, as authorized by Section 4052.03.
</html:p>
<html:p>
(B)
<html:span class="EnSpace"/>
The pharmacist shall notify the patient’s primary care provider of any drugs or devices furnished to the patient, or enter the appropriate information in a patient record system shared with the primary care provider, as permitted by that primary care provider. If the patient does not have a primary care provider, the pharmacist shall provide the patient with a written record of the drugs or devices furnished and advise the patient to consult a physician of the
patient’s choice.
</html:p>
<html:p>
(11)
<html:span class="EnSpace"/>
Administer immunizations pursuant to a protocol with a prescriber.
</html:p>
<html:p>
(12)
<html:span class="EnSpace"/>
Order and interpret tests for the purpose of monitoring and managing the efficacy and toxicity of drug therapies. A pharmacist who orders and interprets tests pursuant to this paragraph shall ensure that the ordering of those tests is done in coordination with the patient’s primary care provider or diagnosing prescriber, as appropriate, including promptly transmitting written notification to the patient’s diagnosing prescriber or entering the appropriate information in a patient record system shared with the prescriber, when available and as permitted by that prescriber.
</html:p>
<html:p>
(13)
<html:span class="EnSpace"/>
Initiate, adjust, or discontinue drug therapy for a patient under
a collaborative practice agreement with any health care provider with prescriptive authority. The collaborative practice agreement may be between a single or multiple pharmacists and a single or multiple health care providers with prescriptive authority.
</html:p>
<html:p>
(14)
<html:span class="EnSpace"/>
Provide medication-assisted treatment pursuant to a state protocol, to the extent authorized by federal law.
</html:p>
<html:p>
(b)
<html:span class="EnSpace"/>
A pharmacist who is authorized to issue an order to initiate or adjust a controlled substance therapy pursuant to this section shall personally register with the federal Drug Enforcement Administration.
</html:p>
<html:p>
(c)
<html:span class="EnSpace"/>
This section does not affect the applicable requirements of law relating to either of the following:
</html:p>
<html:p>
(1)
<html:span class="EnSpace"/>
Maintaining the confidentiality of medical records.
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
The licensing of a health care facility.
</html:p>
</ns0:Content>
</ns0:LawSectionVersion>
</ns0:LawSection>
</ns0:Fragment>
</ns0:BillSection>
<ns0:BillSection id="id_C92F0B1D-5F2B-44DA-ACC9-F60D729233BD">
<ns0:Num>SEC. 3.</ns0:Num>
<ns0:ActionLine action="IS_AMENDED" ns3:href="urn:caml:codes:BPC:caml#xpointer(%2Fcaml%3ALawDoc%2Fcaml%3ACode%2Fcaml%3ALawHeading%5B%40type%3D'DIVISION'%20and%20caml%3ANum%3D'2.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'CHAPTER'%20and%20caml%3ANum%3D'9.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'ARTICLE'%20and%20caml%3ANum%3D'3.'%5D%2Fcaml%3ALawSection%5Bcaml%3ANum%3D'4052.3.'%5D)" ns3:label="fractionType: LAW_SECTION" ns3:type="locator">
Section 4052.3 of the
<ns0:DocName>Business and Professions Code</ns0:DocName>
is amended to read:
</ns0:ActionLine>
<ns0:Fragment>
<ns0:LawSection id="id_A366FC3C-49D6-455B-9D0E-CC94EBEA0484">
<ns0:Num>4052.3.</ns0:Num>
<ns0:LawSectionVersion id="id_4DF74CE8-012E-41BC-9972-5710D7A42B73">
<ns0:Content>
<html:p>
(a)
<html:span class="EnSpace"/>
(1)
<html:span class="EnSpace"/>
Notwithstanding any other law, a pharmacist may furnish self-administered prescription-only hormonal contraceptives in accordance with standardized procedures or protocols developed and approved by both the board and the Medical Board of California in consultation with the American Congress of Obstetricians and Gynecologists, the California Pharmacists Association, and other appropriate entities. The standardized procedure or protocol shall require that the patient use a self-screening tool that will identify patient risk factors for use of self-administered hormonal contraceptives, based on the current United States Medical Eligibility Criteria (USMEC) for Contraceptive Use developed by the federal Centers for
Disease Control and Prevention, and that the pharmacist refer the patient to the patient’s primary care provider or, if the patient does not have a primary care provider, to nearby clinics, upon furnishing a self-administered hormonal contraceptive pursuant to this subdivision, or if it is determined that use of a self-administered hormonal contraceptive is not recommended.
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
The board and the Medical Board of California are both authorized to ensure compliance with this subdivision, and each board is specifically charged with the enforcement of this subdivision with respect to its respective licensees. This subdivision does not expand the authority of a pharmacist to prescribe any prescription medication.
</html:p>
<html:p>
(b)
<html:span class="EnSpace"/>
(1)
<html:span class="EnSpace"/>
Notwithstanding any other law, a pharmacist
may furnish emergency contraception drug therapy in accordance with either of the following:
</html:p>
<html:p>
(A)
<html:span class="EnSpace"/>
Standardized procedures or protocols developed by the pharmacist and an authorized prescriber who is acting within their scope of practice.
</html:p>
<html:p>
(B)
<html:span class="EnSpace"/>
Standardized procedures or protocols developed and approved by both the board and the Medical Board of California in consultation with the American Congress of Obstetricians and Gynecologists, the California Pharmacists Association, and other appropriate entities. The board and the Medical Board of California are both authorized to ensure compliance with this clause, and each board is specifically charged with the enforcement of this provision with respect to its respective licensees. This subdivision does not expand the authority of
a pharmacist to prescribe any prescription medication.
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
Prior to performing a procedure authorized under this subdivision, a pharmacist shall complete a training program on emergency contraception that consists of at least one hour of approved continuing education on emergency contraception drug therapy.
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
A pharmacist, pharmacist’s employer, or pharmacist’s agent shall not directly charge a patient a separate consultation fee for emergency contraception drug therapy services initiated pursuant to this subdivision, but may charge an administrative fee not to exceed ten dollars ($10) above the retail cost of the drug. Upon an oral, telephonic, electronic, or written request from a patient or customer, a pharmacist or pharmacist’s employee shall disclose the total
retail price that a consumer would pay for emergency contraception drug therapy. As used in this paragraph, total retail price includes providing the consumer with specific information regarding the price of the emergency contraception drugs and the price of the administrative fee charged. This limitation is not intended to interfere with other contractually agreed-upon terms between a pharmacist, a pharmacist’s employer, or a pharmacist’s agent, and a health care service plan or insurer. Patients who are insured or covered and receive a pharmacy benefit that covers the cost of emergency contraception shall not be required to pay an administrative fee. These patients shall be required to pay copayments pursuant to the terms and conditions of their coverage. This paragraph shall become inoperative for dedicated emergency contraception drugs if these drugs are reclassified as over-the-counter products by
the federal Food and Drug Administration.
</html:p>
<html:p>
(4)
<html:span class="EnSpace"/>
A pharmacist shall not require a patient to provide individually identifiable medical information that is not specified in Section 1707.1 of Title 16 of the California Code of Regulations before initiating emergency contraception drug therapy pursuant to this subdivision.
</html:p>
<html:p>
(c)
<html:span class="EnSpace"/>
Notwithstanding any other law, a pharmacist may furnish over-the-counter contraceptives without the standardized procedures or protocols that subdivision (a) requires for prescription-only self-administered hormonal contraceptives.
</html:p>
<html:p>
(d)
<html:span class="EnSpace"/>
For each emergency contraception drug therapy or self-administered prescription-only hormonal contraception initiated pursuant to this section, the pharmacist shall
provide the recipient of the drug with a standardized factsheet that includes, but is not limited to, the indications and contraindications for use of the drug, the appropriate method for using the drug, the need for medical followup, and other appropriate information. The board shall develop this form in consultation with the State Department of Public Health, the American Congress of Obstetricians and Gynecologists, the California Pharmacists Association, and other health care organizations. This section does not preclude the use of existing publications developed by nationally recognized medical organizations.
</html:p>
</ns0:Content>
</ns0:LawSectionVersion>
</ns0:LawSection>
</ns0:Fragment>
</ns0:BillSection>
<ns0:BillSection id="id_D6E9F9A2-A183-443C-875D-B3B042DCDFB6">
<ns0:Num>SEC. 4.</ns0:Num>
<ns0:ActionLine action="IS_AMENDED" ns3:href="urn:caml:codes:BPC:caml#xpointer(%2Fcaml%3ALawDoc%2Fcaml%3ACode%2Fcaml%3ALawHeading%5B%40type%3D'DIVISION'%20and%20caml%3ANum%3D'2.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'CHAPTER'%20and%20caml%3ANum%3D'9.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'ARTICLE'%20and%20caml%3ANum%3D'3.'%5D%2Fcaml%3ALawSection%5Bcaml%3ANum%3D'4064.5.'%5D)" ns3:label="fractionType: LAW_SECTION" ns3:type="locator">
Section 4064.5 of the
<ns0:DocName>Business and Professions Code</ns0:DocName>
is amended to read:
</ns0:ActionLine>
<ns0:Fragment>
<ns0:LawSection id="id_D8AB4D1A-8AED-4CCC-B9FA-46EB74B911DB">
<ns0:Num>4064.5.</ns0:Num>
<ns0:LawSectionVersion id="id_60F310D2-543C-4F75-842F-8A0075234DA2">
<ns0:Content>
<html:p>
(a)
<html:span class="EnSpace"/>
A pharmacist may dispense not more than a 90-day supply of a dangerous drug other than a controlled substance pursuant to a valid prescription that specifies an initial quantity of less than a 90-day supply followed by periodic refills of that amount if all of the following requirements are satisfied:
</html:p>
<html:p>
(1)
<html:span class="EnSpace"/>
The patient has completed an initial 30-day supply of the dangerous drug.
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
The total quantity of dosage units dispensed does not exceed the total quantity of dosage units authorized by the prescriber on the prescription, including refills.
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
The
prescriber has not specified on the prescription that dispensing the prescription in an initial amount followed by periodic refills is medically necessary.
</html:p>
<html:p>
(4)
<html:span class="EnSpace"/>
The pharmacist is exercising their professional judgment.
</html:p>
<html:p>
(b)
<html:span class="EnSpace"/>
For purposes of this section, if the prescription continues the same medication as previously dispensed in a 90-day supply, the initial 30-day supply under paragraph (1) of subdivision (a) is not required.
</html:p>
<html:p>
(c)
<html:span class="EnSpace"/>
A pharmacist dispensing an increased supply of a dangerous drug pursuant to this section shall notify the prescriber of the increase in the quantity of dosage units dispensed.
</html:p>
<html:p>
(d)
<html:span class="EnSpace"/>
In no case shall a pharmacist dispense a greater supply
of a dangerous drug pursuant to this section if the prescriber personally indicates, either orally or in their own handwriting, “No change to quantity,” or words of similar meaning. Nothing in this subdivision shall prohibit a prescriber from checking a box on a prescription marked “No change to quantity,” provided that the prescriber personally initials the box or checkmark. To indicate that an increased supply shall not be dispensed pursuant to this section for an electronic data transmission prescription as defined in subdivision (c) of Section 4040, a prescriber may indicate “No change to quantity,” or words of similar meaning, in the prescription as transmitted by electronic data, or may check a box marked on the prescription “No change to quantity.” In either instance, it shall not be required that the prohibition on an increased supply be manually initialed by the prescriber.
</html:p>
<html:p>
(e)
<html:span class="EnSpace"/>
This section shall not apply to psychotropic medication or psychotropic drugs as described in subdivision (d) of Section 369.5 of the Welfare and Institutions Code.
</html:p>
<html:p>
(f)
<html:span class="EnSpace"/>
Except for the provisions of subdivision (d), this section does not apply to FDA-approved, self-administered hormonal contraceptives.
</html:p>
<html:p>
(1)
<html:span class="EnSpace"/>
A pharmacist shall dispense, at a patient’s request, up to a 12-month supply of an FDA-approved, self-administered hormonal contraceptive pursuant to a valid prescription that specifies an initial quantity followed by periodic refills.
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
A pharmacist furnishing an FDA-approved, self-administered prescription-only hormonal contraceptive pursuant to Section 4052.3
under protocols developed by the California State Board of Pharmacy or an over-the-counter contraceptive may furnish, at the patient’s request, up to a 12-month supply at one time.
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
Nothing in this subdivision shall be construed to require a pharmacist to dispense or furnish a drug if it would result in a violation of Section 733.
</html:p>
<html:p>
(g)
<html:span class="EnSpace"/>
Nothing in this section shall be construed to require a health care service plan, health insurer, workers’ compensation insurance plan, pharmacy benefits manager, or any other person or entity, including, but not limited to, a state program or state employer, to provide coverage for a dangerous drug in a manner inconsistent with a beneficiary’s plan
benefit.
</html:p>
</ns0:Content>
</ns0:LawSectionVersion>
</ns0:LawSection>
</ns0:Fragment>
</ns0:BillSection>
<ns0:BillSection id="id_AC484A35-2607-4265-86AD-1833A4ABAC61">
<ns0:Num>SEC. 5.</ns0:Num>
<ns0:Content>
<html:p>This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:</html:p>
<html:p>In order to quickly ensure equitable access to over-the-counter birth control for all Californians, it is necessary that this act take effect immediately.</html:p>
</ns0:Content>
</ns0:BillSection>
</ns0:Bill>
</ns0:MeasureDoc>
|